|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Arthritis, osteoarthritis |
|
Arthritis, rheumatoid |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
agitation |
|
anaphylactic shock |
|
anaphylactoid reactions |
|
anemia |
|
angina |
|
angioedema |
|
anorexia |
|
anxiety |
|
aseptic meningitis |
|
asthenia |
|
azotemia |
|
blurred vision |
|
bullous rash |
|
confusion |
|
constipation |
|
depression |
|
diaphoresis |
|
diarrhea |
|
dizziness |
|
dyspepsia |
|
dysphagia |
|
edema |
|
elevated hepatic enzymes |
|
eosinophilia |
|
eructation |
|
erythema multiforme |
|
esophageal stricture |
|
esophageal ulceration |
|
esophagitis |
|
fatigue |
|
flatulence |
|
gastritis |
|
GI bleeding |
|
GI perforation |
|
headache |
|
heart failure |
|
hematuria |
|
hepatic failure |
|
hepatitis |
|
hyperkalemia |
|
hypertension |
|
hyperuricemia |
|
insomnia |
|
interstitial nephritis |
|
jaundice |
|
leukopenia |
|
malaise |
|
melena |
|
myocardial infarction |
|
nausea/vomiting |
|
nephrotic syndrome |
|
odynophagia |
|
palpitations |
|
pancreatitis |
|
paresthesias |
|
peptic ulcer |
|
photosensitivity |
|
platelet dysfunction |
|
pneumonitis |
|
proteinuria |
|
pruritus |
|
pseudoporphyria |
|
pyrosis (heartburn) |
|
rash (unspecified) |
|
renal failure (unspecified) |
|
renal papillary necrosis |
|
Stevens-Johnson syndrome |
|
syncope |
|
thrombocytopenia |
|
tinnitus |
|
toxic epidermal necrolysis |
|
tremor |
|
urticaria |
|
vasculitis |
|
vertigo |
|
visual impairment |
|
xerostomia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
acute bronchospasm |
|
alcoholism |
|
anemia |
|
anticoagulant therapy |
|
asthma |
|
bone marrow suppression |
|
breast-feeding |
|
cardiac disease |
|
cerebrovascular disease |
|
chemotherapy |
|
coagulopathy |
|
corticosteroid therapy |
|
dehydration |
|
dental disease |
|
dental work |
|
diabetes mellitus |
|
edema |
|
elderly |
|
GI bleeding |
|
GI disease |
|
heart failure |
|
hematological disease |
|
hemophilia |
|
hepatic disease |
|
hypertension |
|
hypovolemia |
|
immunosuppression |
|
intramuscular injections |
|
jaundice |
|
labor |
|
myocardial infarction |
|
nasal polyps |
|
neutropenia |
|
peptic ulcer disease |
|
peripheral edema |
|
peripheral vascular disease |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
rheumatoid arthritis |
|
stroke |
|
surgery |
|
systemic lupus erythematosus (SLE) |
|
thrombocytopenia |
|
tobacco smoking |
|
ulcerative colitis |
|
|
ADULT DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Oral, initially 1000 mg a day, as a single dose (usually at night) or in two divided doses (in the morning and evening). Dosage may be increased, if necessary, to 1500 mg or 2000 mg a day in two divided doses. After a satisfactory response has been obtained, dosage should be individualized according to patient tolerance and response. The lowest dose that provides continuing control of symptoms should be used for maintenance. |
|
MAXIMUM ADULT DOSE:
|
|
Doses larger than 2000 mg a day have not been studied and are not recommended.
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Oral, initially 1000 mg a day, as a single dose (usually at night) or in two divided doses (in the morning and evening). Dosage may be increased, if necessary, to 1500 mg or 2000 mg a day in two divided doses. After a satisfactory response has been obtained, dosage should be individualized according to patient tolerance and response. The lowest dose that provides continuing control of symptoms should be used for maintenance. |
|
|
|
|